Patents Examined by Padmavathi Baskar
  • Compositions and methods for treating clostridium difficile infection
    Patent number: 10758591
    Abstract: Clostridium difficile infection is the leading cause of hospital acquired antibiotic-associated diarrhea in the US (Bartlett, in 2006). The increased prevalence of circulating C. difficile strains poses a significant health threat to US health care facilities. Strains expressing the toxin C. difficile Transferase (CDT), in addition to Toxins A and B (TcdA and TcdB), are more virulent and are associated with higher mortality rates (Bacci et al., 2011). We recently identified a protective role for eosinophils against C. difficile pathogenesis (Buonomo et al., 2016). We have also defined CDT's ability to increase host inflammation and suppress protective eosinophils through a TLR2 dependent mechanism (Cowardin et al., 2016). How CDT promotes virulence and eosinophil suppression via TLR2 is still under investigation.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: September 1, 2020
    Assignee: University of Virginia Patent Foundation
    Inventors: Alyse Longtin Frisbee, William A. Petri, Jr.
  • Synthetic antibodies to BAX and uses thereof
    Patent number: 10759851
    Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 1, 2020
    Assignees: ALBERT EINSTEIN COLLEGE OF MEDICINE, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
  • Antibodies targeted to fungal cell wall polysaccharides
    Patent number: 10752704
    Abstract: A compound comprising one or more polysaccharide moieties each independently represented by the formula ?(1?4)-[GlcNH—R]n-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: August 25, 2020
    Assignee: Wellstat Vaccines, LLC
    Inventors: Francis Michon, Samuel J. Wohlstadter, Frank Comer, Kuishu Ren
  • DNA vector and transformed tumor cell vaccines
    Patent number: 10751400
    Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 25, 2020
    Assignee: MORPHOGENESIS, INC.
    Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
  • RHTB protein variants and the method of producing O-phosphoserine using the same
    Patent number: 10752659
    Abstract: The present invention relates to an RhtB (homoserine/homoserine lactone export transporter) protein variant having an enhanced ability to export O-phosphoserine (OPS) that is a precursor of L-cysteine, a polynucleotide encoding the protein, a vector comprising the polynucleotide, an OPS-producing microorganism comprising the protein variant, a method of producing O-phosphoserine using the microorganism, and a method for preparing cysteine or its derivatives, which comprises reacting O-phosphoserine, produced by the method above, with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism that expresses OPSS.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: August 25, 2020
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Sol Kim, Hye Won Kim, Jin Sook Chang, In Hwa Yoo
  • OmpA and Asp14 in vaccine compositions and as diagnostic targets
    Patent number: 10736951
    Abstract: Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: August 11, 2020
    Assignee: Virginia Commonwealth University
    Inventor: Jason A. Carlyon
  • RHTB protein variants and the method of producing O-phosphoserine using the same
    Patent number: 10738091
    Abstract: The present invention relates to an RhtB (homoserine/homoserine lactone export transporter) protein variant having an enhanced ability to export O-phosphoserine (OPS) that is a precursor of L-cysteine, a polynucleotide encoding the protein, a vector comprising the polynucleotide, an OPS-producing microorganism comprising the protein variant, a method of producing O-phosphoserine using the microorganism, and a method for preparing cysteine or its derivatives, which comprises reacting O-phosphoserine, produced by the method above, with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism that expresses OPSS.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 11, 2020
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Sol Kim, Hye Won Kim, Jin Sook Chang, In Hwa Yoo
  • Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
    Patent number: 10729731
    Abstract: Bacterial strains are provided having at least one of a reduced size, a sialic acid coat, inducibly altered surface antigens, and expression of PD-L1 or CTLA-4 antagonists and/or tryptophanase. The bacteria may have improved serum half-life, increased penetration into tumors, increased tumor targeting and increased antitumor activity. The bacteria are useful for delivery of therapeutic agents that treat of neoplastic diseases including solid tumors and lymphomas.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: August 4, 2020
    Inventor: David Gordon Bermudes
  • Programmable drug delivery profiles of tumor-targeted bacteria
    Patent number: 10731125
    Abstract: The present invention relates to composition comprising at least one non-pathogenic bacterial cell, wherein the non-pathogenic bacterial cell comprises at least a first and a second nucleic acid sequence, the first nucleic acid sequence comprising at least one non-constitutive promoter operably linked to the second nucleic acid sequence that encodes therapeutic agent, wherein the non-constitutive promoter is an inducible promoter responsive to at least one stimuli and the at least one stimuli comprises the presence of a certain density or a certain number of bacterial cells comprising the first and second nucleic acid sequences.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: August 4, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Sangeeta N. Bhatia, Tal Danino
  • Bioactive polypeptides for improvements in plant protection, growth and productivity
    Patent number: 10717767
    Abstract: Bioactive priming polypeptides are provided that are useful when applied to plants in agricultural formulations. Methods of using the formulations containing the bioactive priming polypeptides are also provided which are applied exogenously to the surface of a plant or a plant cell membrane or endogenously to the interior of a plant or to a plant cell. The bioactive priming polypeptides when applied to a plant, a plant part, or a plant growth medium or a rhizosphere in an area surrounding the plant or the plant part increase growth, yield, health, longevity, productivity, and/or vigor of a plant or a plant part and/or decrease abiotic stress in the plant or the plant part and/or protect the plant or the plant part from disease, insects and/or nematodes, and/or increase the innate immune response of the plant or the plant part and/or change plant architecture.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: July 21, 2020
    Assignee: Spogen Biotech, Inc.
    Inventors: Brian Thompson, Michelle Leslie
  • Chlamydia antigens
    Patent number: 10716842
    Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CTI 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: July 21, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Guido Grandi, Renata Maria Grifantini, Oretta Finco
  • Process for preparing pneumococcal polysaccharide-protein conjugates
    Patent number: 10716848
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: July 21, 2020
    Assignee: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
  • Chlamydomonas mutants produced using RGEN RNP and method for preparing pigment using the same
    Patent number: 10709152
    Abstract: The present invention relates to a new alga having an improved ability to produce a pigment, and when a mutant of the present invention is used, a carotenoid-based pigment, specifically, a xanthophyll can be produced by consuming less energy, so that it is possible to efficiently produce the pigment at the industrial level. Further, the pigment can be applied as a raw material for a food, a health functional food and a medicine, which include the pigment. In particular, since a DNA fragment is not likely to be inserted into a target base sequence or a base sequence other than the target, it is expected that the procedure of constructing the mutant is not regulated as a GMO, so that it is expected that the procedure of constructing the mutant can create a big economic effect in terms of an industry which produces lutein and zeaxanthin by using microalgae.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: July 14, 2020
    Assignee: Industry-University Cooperation Foundation Hanyang University
    Inventors: Eon Seon Jin, Sang Su Bae, Kwang Ryul Baek, Duk Hyoung Kim, Joo Yeon Jeong
  • Compositions and methods for treatment of pain
    Patent number: 10704035
    Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 7, 2020
    Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology
    Inventors: R. John Collier, Isaac Chiu, Bradley L. Pentelute
  • Thermophilic and thermoacidophilic metabolism genes and enzymes from and related organisms, methods
    Patent number: 10689638
    Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for modulating or altering metabolism in a cell using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: June 23, 2020
    Inventors: Vicki S. Thompson, William A. Apel, Jeffrey A. Lacey, Brady D. Lee, David W. Reed, Francisco F. Roberto, David N. Thompson
  • Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
    Patent number: 10688149
    Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: June 23, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Ruchi Mathur, Christopher Chang
  • Proteins and nucleic acids useful in vaccines targeting
    Patent number: 10675340
    Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 9, 2020
    Assignee: Evaxion Biotech ApS
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Methods of treating and preventing infections and associated conditions
    Patent number: 10669329
    Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: June 2, 2020
    Assignee: New York University
    Inventors: Victor J. Torres, Francis Alonzo, III
  • Immunomodulatory composition comprising bifidobacteria
    Patent number: 10668117
    Abstract: The present invention relates to composition derivable from a bifidobacteria, methods and uses thereof, for use in modulating the immune system in a subject by affecting viral action and/or viral effects in said subject. Furthermore, said composition may also be used in reducing the risk of development and exacerbation of chronic respiratory diseases such as asthma and COPD in a subject; preferably by modulating the immune system in the subject by affecting viral action and/or viral effects in said subject.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: June 2, 2020
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Markus Lehtinen, Sampo Lahtinen, Ronald B. Turner
  • Combination and/or comprising bacillus, and yucca, quillaja, or both and a method for using and making
    Patent number: 10660930
    Abstract: The present disclosure concerns embodiments of a combination and/or composition comprising bacillus, and yucca, quillaja or both. Embodiments of methods of making and using the combination and/or composition also are disclosed herein. In some embodiments, the combination and/or composition may be used to improve feed conversion rates in animals. In some embodiments the animals are avians; in other embodiments, the animals are non-avians. Embodiments of the disclosed combination can comprise a first composition comprising Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans. Embodiments of the disclosed composition can comprise Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: May 26, 2020
    Assignees: Phibro Animal Health Corporation, Desert King International LLC
    Inventors: David Calabotta, Wendell Knehans, Derek McLean